Paige develops a digital pathology platform that utilizes generative AI to enhance cancer diagnosis and biomarker discovery by analyzing digitized tissue images. The platform improves diagnostic accuracy, reduces detection errors by 70%, and significantly shortens the time to diagnosis, thereby supporting pathologists in delivering timely and precise patient care.
Funding
$239.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JJKKFounders
Product
Problem
Pathologists face increasing workloads and time constraints while striving to deliver accurate and timely cancer diagnoses. Traditional pathology methods can be prone to errors, and the detection of subtle cancerous changes in tissue samples can be challenging. This can lead to delays in diagnosis and treatment, potentially impacting patient outcomes.
Solution
Paige offers a digital pathology platform that leverages generative AI to enhance cancer diagnosis and biomarker discovery through the analysis of digitized tissue images. The platform provides AI-powered applications that assist pathologists in the detection, classification, and subtyping of cancers, as well as the identification of molecular biomarkers. By integrating cutting-edge AI with intuitive tools, Paige streamlines pathology workflows, reduces the potential for errors, and enables pathologists to make more informed and confident diagnoses. The platform's AI models are trained on vast datasets of digitized slides, allowing for the detection of subtle patterns and anomalies that may be missed by the human eye. Paige also offers a multimodal co-pilot, Alba, which uses voice and text commands to further streamline the diagnostic process.
Target Audience
The primary target audience includes pathologists, hospitals, and laboratories seeking to improve diagnostic accuracy, reduce errors, and streamline pathology workflows, as well as pharmaceutical and life science companies looking to accelerate cancer research and drug development.
Features
- AI-powered diagnostic applications for prostate, breast, and gastrointestinal cancers, as well as a PanCancer suite for multiple tissue types
- Biomarker AI applications for the detection of molecular biomarkers directly from tissue samples
- Paige Alba, a multimodal co-pilot that integrates AI with voice and text commands to streamline workflows
- Foundation models, including Virchow and PRISM, trained on over 1.5 million slides
- PanCancer AI modules for therapeutic targeting, biomarker identification, and clinical trial design
- FullFocus® platform for digital pathology workflow management
- AI Technology & Services for custom AI model development, regulatory strategy, and commercialization